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which are a group of complications caused by 
mitochondrial dysfunction. Mitochondrial diseases 
are also caused by mutations in the mitochondria 
affecting mitochondrial function. Mutations in 
mitochondria are also facilitated by high level of 
oxidative stress.[15]
Melatonin has been shown to play a crucial role in 
regulation of mitochondrial homeostasis. Melatonin, 
in addition to being a powerful antioxidant, decreases 
nitric oxide (NO) generation in mitochondria and 
maintains bioenergetic functions of the cell.[16,17]
The purpose of the current study was to identify 
melatonin production, metabolism, and clinical effects in 
diseases related to mitochondrial dysfunction including 
diabetes, cancer, and diseases related to brain function. 
Furthermore, the mechanisms through which melatonin 
can exert neuroprotection against neurodegenerative 
disorders related to mitochondrial dysfunctions are 
reviewed.
INTRODUCTION
Enhanced generation of reactive oxygen species (ROS) 
is considered as one of the main contributory factors in 
a wide variety of diseases and age‑related degeneration. 
Oxidative stress induced by these free radicals has been 
implicated in etiology of cancer,[1,2] diabetes mellitus,[3,4] 
cardiovascular diseases, [5,6] neurodegenerative 
diseases,[7,8] neuropsychological disorders,[9,10] and 
infectious disease.[11,12]
Mitochondria are considered as the main source 
of ROS/reactive nitrogen species (RNS) generators 
which are the predominant target of their actions, 
resulting in widespread damage to mitochondrial 
respiratory chain. This process produces further 
increase in free radical generation, causing a 
self‑induced vicious cycle.[13,14] This process and some 
other conditions may cause mitochondrial diseases 
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MITOCHONDRIA AND FREE RADICAL GENERATION 
IN MITOCHONDRIA
The main function of mitochondria is production of 
adenosine triphosphate (ATP) through the electron 
transport chain (ETC). The primary function of the ETC 
is conversion of redox energy to an electrochemical 
gradient which causes synthesis of ATP from adenosine 
diphosphate and production of phosphate by ATP synthase. 
The ultimate generation of the respiratory chain is water 
which is produced in a four‑electron reduction of molecular 
oxygen (O2). During this process, a section of O2 is converted 
to ROS, including superoxide anion radical (O2•−), reactive 
hydroxyl radical (•OH), and hydrogen peroxide (H2O2).[18]
Mitochondrial NO synthase (NOS) is responsible for 
production of NO radical (•NO) from L‑arginine. The free 
radical •NO is produced by several forms of NOS. •NO is able 
to easily cross membranes and enter mitochondria regardless 
of its origin. •NO can strongly interfere with the respiratory 
chain components such as cytochrome C‑oxidase.[19]
These free radicals can damage proteins of respiratory 
complexes. When •NO reaches high levels, it can start 
free radical‑mediated chain reactions which destroy 
DNA molecules, proteins, and lipids.[19,20] Damage to the 
mitochondrial respiratory chain leads to further generation 
of free radicals and breakdown of proton potential, 
apoptosis, and cell death.[21]
Free radicals are usually generated in cells during normal 
activity. Among the mechanisms which control the ROS/
RNS production is the enzyme superoxide dismutase 
function in mitochondrial membrane that removes O2•−. 
The •OH generated from H2O2 is scavenged by glutathione 
peroxidase (GPx).[22] These enzymes which are the important 
parts of antioxidant defense system reduce free radicals 
within the mitochondria.
Antioxidants such as Vitamins C and E are able to participate 
in the antioxidant defense system of mitochondria, but they 
cannot convert O2•− to O2. It is glutathione (GSH) which 
scavenges O2•−, as well as participating in several redox 
reactions. In the mitochondria, the redox cycling is very 
active and prevents significant loss of GSH. This process is 
very important because the mitochondrial GPx and GSH 
reductase activities depend only on GSH uptake from the 
cytoplasm for keeping adequate GSH levels. Melatonin, by 
stimulating the activity of the enzyme γ‑glutamyl‑cysteine 
synthetase, promotes synthesis of GSH.[23] It also plays an 
important role in mitochondrial physiology through its 
effects on gene expression of GPx, GSH reductase, catalase, 
and dismutase, helping in maintaining the GSH/GSSG ratio 
and in high recycling of GSH.[17,24]
MELATONIN AND REDUCTION OF OXIDATIVE 
STRESS
Free radicals are atoms or molecules with unpaired electrons 
which make them highly toward other substances. Free 
radicals such as H2O2 and •OH which are called ROS can 
cause oxidative stress and damage to cell components.[25‑27] 
Increased production of ROS and other free radicals 
or decreased antioxidant enzymes can cause oxidative 
damages to organs, tissues, and various cells such as brain, 
heart, and vascular cells.[28‑30] Oxidative stress is also the 
background of many hard curable diseases such as high 
blood pressure,[31,32] atherosclerosis,[32,33] and infectious 
diseases.[34‑36]
ROS are mostly produced in the mitochondria as normal 
cell respiration. The interrelationship between mitochondria 
and its ROS generation suggests shared pathogenic 
mechanisms in ROS‑related diseases and mitochondria.[37]
In this regard, mitochondria are considered as endogenous 
producers of ROS and the central executioners of cell 
death. Increased mitochondrial Ca2 − overload is associated 
with generation of superoxide which induces the release 
of pro‑apoptotic proteins implicated in pathogenesis of 
neurodegenerative diseases and several features of cell death.[38]
Antioxidants such as Vitamins A, C, and E have a little 
ability to protect the body against free radicals. In 
preclinical studies, plants’ antioxidants have been effective 
in most of ROS‑related diseases such as gastrointestinal 
complications,[39‑42] cognitive problems,[43,44] cardiovascular 
diseases,[45,46] pain,[10,47] and other complications.[48‑50] 
However, their effects have not been confirmed in most 
of large clinical trials.[29] Melatonin has been shown to 
possess high level of antioxidant activity and the ability 
to counteract with oxidative stress‑induced diseases, even 
in most of clinical trials.[13,17] Melatonin is the stimulator 
of antioxidant enzymes including superoxide dismutase, 
GPx, GSH reductase, and catalase. It also acts as inhibitor of 
lipoxygenase. Melatonin can cause resistance to oxidation 
damage by fixing the microsomal membranes.[51]
Administration of melatonin in animals with ischemia can 
reduce malondialdehyde level and other products obtained 
from the membrane lipid peroxidation as injury indices.[52] 
Features that help melatonin to prevent lipid peroxidation 
include being soluble in fat, hydroxyl free radical clearing, 
inhibition of lipid peroxidation, and increasing the effectiveness 
of other antioxidants such as Vitamin E and C, clearing of 
peroxide radicals, and also individual highly reactive oxygen.
[53] Melatonin also increases the level of GSH and GSH 
S‑transferase and the activity of GPx.[17] Melatonin can cross 
blood–brain barrier and placenta easily and reach all the cellular 
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components without difficulty. Hence, it can protect the cell 
walls, organs, and nuclei against the damage of free radicals.[13]
PHARMACOLOGIC AND THERAPEUTIC ASPECTS 
OF MELATONIN
Melatonin was first considered as a hormone responsible 
for control of circadian rhythms. However, it has several 
biological functions which are produced by activation 
of its receptors or due to melatonin role as a powerful 
antioxidant. Melatonin has a specific role in the protection 
of mitochondrial DNA and other biological compounds.[54]
Melatonin is now used for insomnia, especially the insomnia 
associated with attention‑deficit hyperactivity disorder, 
insomnia caused by beta‑blockers, delayed sleep phase 
syndrome, rapid eye movement sleep behavior disorder, 
and the sleep difficulties in children associated with 
developmental disorders such as intellectual disabilities, 
autism, and cerebral palsy. Melatonin is also used to reduce 
the side effects of stopping smoking or as a sleep remedy 
after stopping the consumption of benzodiazepines. It might 
also be used for mild mental impairment, bipolar disease, 
depression, seasonal affective disorder, Alzheimer’s disease, 
schizophrenia, epilepsy, dementia, stress, delirium, chronic 
obstructive pulmonary disease, endometriosis, fibromyalgia, 
tinnitus, nonalcoholic liver disease, chronic fatigue 
syndrome, age‑related vision loss, restless leg syndrome, 
jaw pain, nerve pain, weakness, sarcoidosis, migraine and 
tension headache, benign prostatic hyperplasia, irritable 
bowel syndrome, osteoporosis, tardive dyskinesia, acid 
reflux disease, infertility, aging, menopause, metabolic 
syndrome, inflammatory bowel disease (IBD). Recovery 
after surgery, agitation due to anesthesia, inability to 
control urination, various cancers including breast, brain, 
lung, prostate, head, neck, and gastrointestinal tract 
cancers. Melatonin is also used to reduce some side effects 
of cancer chemotherapies such as weight loss, fatigue and 
thrombocytopenia, too.[55‑69]
Regarding the aim of the current study, the effects of 
melatonin on the most important diseases related to 
mitochondrial dysfunction including cancer, cardiovascular 
disease, Alzheimer’s disease, obesity, diabetes mellitus, 
affective disorder, gastrointestinal diseases, attention‑deficit, 
hyperactivity disorder, and autism are discussed below. The 
melatonin side effects are also presented at the end.
Melatonin and cancer
The removal of the pineal gland leads to an increased tumor 
growth while taking melatonin reverses this effect and 
inhibits tumor genesis induced by carcinogen. Melatonin 
is likely to reduce the growth of the tumor cells through 
inhibiting mitosis and regulating the activity of the receptors 
in tumor cells. For example, this hormone inhibits the activity 
and expression of estrogen receptor genes in breast cancer 
cells.[56] Adding melatonin to tamoxifen has led to slow down 
the rate of progression of the disease. Consumption of high 
dose of melatonin (700 mg daily) caused a transient reduction 
in the size of some tumor populations. In addition, it is noted 
that added melatonin to chemotherapy and radiotherapy 
had the influence to reduce the injuries imposed on blood 
cells and made the remedy more tolerable.[56,57]
Researches results have shown that serum and urine 
melatonin levels in women with breast cancer are low and 
melatonin usage could inhibit breast tumor growth.[58] A 
research finding showed that interrupted sleep at 1:30 A.M. 
led to increase in the concentration of estradiol in the blood 
while exposure to light at night reduced the menstrual cycle 
duration. This was accompanied by increasing the risk of 
breast cancer. It was also reported that the prostate cancer 
cells treated with melatonin might significantly reduce the 
number of prostate cancer cells.[59]
Large intestine tumor is one of the tumors that melatonin 
can have effect on it. The mammalian intestine is the place 
of melatonin production, and an impaired circadian rhythm 
of melatonin secretion has been observed in patients with 
colorectal cancer. An inhibitory effect of melatonin on 
colon cancer cell was observed through reduced invasion 
and increased differentiation of cancer cells.[60] Other 
epidemiological studies have shown that melatonin in 
children who have exposed to low frequency magnetic field 
and its risk is lower and leukemia is higher than normal.[61]
Melatonin and cardiovascular disease
The finding that melatonin receptors are found in human 
arteries may suggest a direct role of this hormone in locally 
controlling the blood vessel diameter. According to the 
performed researches, very high concentrations of melatonin 
decrease the risk of atherosclerosis disease with inhibiting 
the oxidation of cholesterol low‑density lipoprotein (LDL).
[62] Circadian changes in hemodynamic parameters including 
heart rate, cardiac output, and blood pressure are clear. 
In addition, the occurrence of some acute cardiovascular 
events such as myocardial infarction and sudden cardiac 
death showed a circadian pattern as the occurrence of such 
cutting off blood flow is greater in the early morning.[18] 
Further, melatonin levels in patients with stroke, migraine, 
and cardiovascular disease will be reduced.[18]
Melatonin and Alzheimer’s disease
Melatonin serum levels and its daily rhythm are reduced 
in patients affected with Alzheimer’s disease. Therefore, in 
these patients, melatonin supplementation might reduce 
distractions and improve their memory. Studies have shown 
that inflammation causes Alzheimer’s disease while taking 
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melatonin orally reduces progression of Alzheimer’s disease 
by decreasing pro‑inflammatory cytokines.[63]
The findings of a research have shown that exposure to 
bright light in the elderly can improve sleep and behavioral 
disorders, depression, and the memory condition. In 
addition, it would shorten the time to fall asleep and increase 
sleep duration for a period of 27 min. It also reduces the time 
of waking. Both factors (light and melatonin) help improve 
the quality of sleep and night vision disturbances.[64]
Melatonin and obesity
Melatonin can affect body size, obesity, and energy intake; 
however, these effects sometimes are different based on the 
species. The direct effect of melatonin is possibly on brown 
fat while its indirect effect found to be through sympathetic 
system. However, this effect is less discernible in the species 
whose activity and life do not depend on light. Melatonin 
increases sensitivity to insulin. This increased insulin 
sensitivity and decreased plasma triglyceride may be due 
to the effect of weight loss caused by melatonin.[65]
As mentioned earlier, plasma melatonin is decreased with 
increasing age; however, the level of leptin and visceral fat 
and nonfasting insulin increases. In a study, daily melatonin 
supplementation for 10 weeks resulted in decrease in 
leptin, nonfasting insulin, and visceral fat, which based 
on the conducted studies, the mentioned reduction was 
in response to melatonin supplements independent on 
changes in the regulation of testicular, thyroid, adrenal, 
and somatotropin.[66]
Melatonin and diabetes mellitus
Administration of melatonin to middle‑aged rats reduced 
visceral fat, plasma insulin, insulin‑like growth factor, and 
leptin levels. In addition, administration of melatonin to 
women after menopause has been shown to decrease insulin 
sensitivity and glucose tolerance. Melatonin increases 
carbohydrate utilization in liver and decreases hepatic 
lipolysis. Long‑term treatment with melatonin led to 
increase insulin doses, triglycerides, leptin, cholesterol and 
high‑density lipoprotein (HDL), esterified cholesterol, free 
cholesterol, and total cholesterol. High doses of melatonin 
inhibited the oxidation of LDL cholesterol.[51]
Melatonin and affective disorder
During pregnancy and after childbirth, some degrees 
of depression with unknown etiology are common. In 
pregnant women with severe depression, the plasma 
melatonin level during night, especially at early morning 
hours, was found to be lower than that of healthy people. 
In severe depression, the sensitivity to estradiol or 
progesterone effects on melatonin receptors will decrease. 
Therefore, increased sexual hormones during pregnancy 
and melatonin secretion in healthy pregnant women will 
increase; however, in patients with severe depression, it does 
not work.[67] A study showed that decreased tryptophan 
followed by diminished serotonin will decrease melatonin 
secretion.[6] Decreased melatonin is also associated with 
different affective disorders. Low‑melatonin syndrome 
or melatonin deficiency depression has been reported 
in a subgroup of depressed patients.[68] Administration 
of melatonin to unresponsive depressed patients to 
conventional drugs was also effective on their depression 
and their sleep quality.[69]
Melatonin and gastrointestinal diseases
It has been reported that melatonin supplements can reduce 
the risk of stomach ulcers. In the case of more severe ulcers, 
the melatonin concentrations in samples were lower than 
that of control group.[68]
Administration of melatonin is effective in reduction of 
damage to the oral cavity tissues through converting free 
radicals to inactive forms. Furthermore, pharmacological 
dosages of melatonin with increased expression of 
endogenous antioxidant enzymes such as GPx, superoxide 
dismutase, and catalase can be effective in the treatment 
of inflammatory lesions after the oral cavity surgery 
including dental extraction. Researchers have shown 
that the application of exogenous melatonin in an animal 
model prevented the stress‑induced gastric damage and 
accelerated stomach ulcer healing by increasing blood 
flow and mucus retention. They also reported the effect of 
melatonin in prevention of esophageal damages caused by 
acid, pepsin, and bile solutions.[12]
Melatonin and attention‑deficit hyperactivity disorder
Attention‑deficit disorder occurs in two forms, with 
or without hyperactivity. People with attention‑deficit 
disorders have been found with specific behaviors such 
as lack of attention to the audience, frequent mistakes 
in homework and career, distraction and forgetting 
distinguishing them from others.[70]
In a study done in 2006 to determine the association 
between attention‑deficit disorder and sleep disorders, it 
was observed that in 25% of children with attention‑deficit, 
hyperactivity disorder suffers from sleep disorders. The 
use of melatonin in such children improved their sleep and 
resulted in eliminating the symptoms.[71]
Melatonin and autism
The serum melatonin level in autistic children (a neurological 
disorder that is characterized by abnormalities in social 
behavior and communication) is lower than healthy 
children. In a survey conducted in this field reported 
that plasma melatonin concentration found to be low in 
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healthy parents of patients with autism suggesting a genetic 
origin. These patients suffer from irregular sleep‑wake 
circadian cycle which can be improved by melatonin 
supplementation.[72]
Melatonin safety and interactions
Melatonin is an inexpensive and safe medication. Except a 
couple of studies which reported transient or mild adverse 
effects in a small number of subjects, other studies did not 
report any adverse effect for it. The side effects reported 
for melatonin include dizziness, confusion, daytime 
sleepiness, headache, irritability, mild anxiety abdominal 
discomfort, and short‑lasting feelings of depression.[55,73] 
Drug interactions of melatonin with other medications have 
been reported for anticoagulants, immunosuppressants, 
antidiabetes, and birth control pills.[74]
Melatonin is one of the normal components of breast milk 
and is synthesized from tryptophan. Although the maternal 
use of melatonin during breastfeeding seems to be safe, 
there are no enough data to make its usage sure. The safety 
usage of melatonin during pregnancy is the same.[74]
DISCUSSION
Mitochondrial dysfunction is one of the main causative 
complications of a lot of diseases, especially the 
neurodegenerative diseases.[29] The main cause of these 
diseases is free radical‑induced oxidative stress.[75,76]
Fee radical theory of aging and degenerative diseases 
attributes the damage to cellular components through 
ROS imbalance as a major determinant of life span 
and disease. Among the possible affecting organs, the 
brain and cell membranes possess high proportion 
of easily peroxidizable fatty acids; hence, they are 
the main targets for oxidative stress. Phospholipids 
including phosphatidylinositol, phosphatidylcholine, 
phosphatidylserine, phosphatidylethanolamine, and 
sphingomyelin make the most abundant content of cellular 
membrane. Therefore, extensive and persistent oxidative 
damage in the brain and cell membranes may easily cause 
the death of these cells.[77]
Antioxidant therapy is a way for slowing the oxidative 
damage that is responsible for functional decline or death of 
the cells or organs. Endogenous antioxidant defense system 
reduces free radicals within the mitochondria. However, in 
extensive oxidative stresses, the endogenous antioxidants 
should be restored. Various antioxidants have been 
extensively examined against oxidative‑induced damage.[31,76] 
Antioxidants such as Vitamins C and E are able to participate 
in the antioxidant defense system of mitochondrial; however, 
in most cases, they are not effective. For example, they cannot 
convert O2•− to O2, and for this process, GSH is needed. The 
mitochondrial GPx and GSH reductase activities depend only 
on GSH uptake from the cytoplasm to keep adequate GSH 
levels. Melatonin by stimulating the activity of the enzyme 
γ‑glutamyl‑cysteine synthetase promotes synthesis of GSH.[23] 
It also plays an important role in mitochondrial physiology 
through its effects on gene expression of GPx, GSH reductase, 
catalase, and dismutase, helping in maintaining the GSH/
GSSG ratio and in high recycling of GSH.[17,24]
More importantly, melatonin is selectively taken up by 
mitochondria and acts as a powerful antioxidant. Furthermore, 
melatonin increases the permeability of membranes and acts 
as inhibitor of lipoxygenase. Melatonin also acts as stimulator 
of antioxidant enzymes including superoxide dismutase, 
GPx, GSH reductase, and catalase. Melatonin has been 
effective against a wide variety of pathological conditions.[1] 
It is also effective on the activity of fibroblasts and stimulates 
the synthesis of Type I collagen fibers[12] as well as puberty 
timing. Activation of melatonin receptors prevents from 
many fatal diseases by increasing the release of some immune 
system inhibitor cytokines due to stress.[12] Melatonin can 
cause to resistance against oxidative damages by stimulating 
the antioxidant enzymes and microsomal membranes 
stabilization.[16] Melatonin is considered to have protective 
effects against the damage caused by ultraviolet radiation.[19]
Based on the performed examinations, melatonin reduces the 
risk of atherosclerosis.[24] In patients with Alzheimer’s disease, 
the use of melatonin supplements could reduce the distraction 
and improve memory in such patients.[25] It was revealed 
that melatonin could influence the body size, obesity, and 
energy intake as well.[28] According to the previous studies, 
received melatonin led to decrease enhanced insulin doses, 
triglycerides, and leptin, while increased HDL cholesterol, 
esterified cholesterol, free cholesterol, and total cholesterol, 
and inhibited the oxidation of LDL cholesterol.[16] The use of 
melatonin could improve sleep and remove attention‑deficit 
hyperactivity disorder symptoms, as well as irregular 
circadian sleep‑wake circle in patients with autism.[11] More 
importantly, melatonin is relatively an inexpensive and safe 
medication, and although it is not sure, it seems to be safe to 
use during pregnancy and lactation.[74]
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